Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 7, 2007, Pages 1356-1362

  Chertkow, Yael ^a,b   Weinreb, Orly ^b   Youdim, Moussa B H ^b   Silver, Henry ^a  

^a Shaar Menashe Brain Behavior Laboratory   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Antipsychotic; Chemokine receptors; G proteins; Schizophrenia; SSRI

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; COMPLEMENTARY DNA; FLUVOXAMINE; G PROTEIN COUPLED RECEPTOR; MESSENGER RNA; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DNA MICROARRAY; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION; GENETIC SCREENING; GENETIC TRANSCRIPTION; HUMAN; MALE; NEGATIVE SYNDROME; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; DNA PRIMERS; DNA, COMPLEMENTARY; DRUG THERAPY, COMBINATION; FEMALE; FLUVOXAMINE; GENE EXPRESSION; HUMANS; MALE; MONOCYTES; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SCHIZOPHRENIA;

EID: 34548120222     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.04.016     Document Type: Article

References (55)

1. Andersen C.L., Jensen J.L., and Orntoft T.F. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64 (2004) 5245-5250
2. Avissar S., Roitman G., and Schreiber G. Differential effects of the antipsychotics haloperidol and clozapine on G protein measures in mononuclear leukocytes of patients with schizophrenia. Cell Mol Neurobiol 21 (2001) 799-811
3. Barak V., Barak Y., Levine J., Nisman B., and Roisman I. Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. J Basic Clin Physiol Pharmacol 6 (1995) 61-69
4. Bas A., Forsberg G., Hammarstrom S., and Hammarstrom M.L. Utility of the housekeeping genes 18S rRNA, beta-actin and glyceraldehyde-3-phosphate-dehydrogenase for normalization in real-time quantitative reverse transcriptase-polymerase chain reaction analysis of gene expression in human T lymphocytes. Scand J Immunol 59 (2004) 566-573
5. Benzing T., Brandes R., Sellin L., Schermer B., Lecker S., Walz G., et al. Upregulation of RGS7 may contribute to tumor necrosis factor-induced changes in central nervous function. Nat Med 5 (1999) 913-918
6. Bowden N.A., Weidenhofer J., Scott R.J., Schall U., Todd J., Michie P.T., et al. Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. Schizophr Res 82 (2006) 175-183
7. Bowden N.A., Scott R.J., and Tooney P.A. Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia. Schizophr Res 89 (2007) 165-168
8. Broadbelt K., Ramprasaud A., and Jones L.B. Evidence of altered neurogranin immunoreactivity in areas 9 and 32 of schizophrenic prefrontal cortex. Schizophr Res 87 (2006) 6-14
9. Brown A.S., Hooton J., Schaefer C.A., Zhang H., Petkova E., Babulas V., et al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry 161 (2004) 889-895
10. Chertkow Y., Weinreb O., Youdim M.B., and Silver H. The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex. Int J Neuropsychopharmacol (2005) 1-10
11. Chertkow Y., Weinreb O., Youdim M.B., and Silver H. Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment. J Neural Transm (2007) 10.1007/s00702-007-0753-1
12. Dean B., Hussain T., Hayes W., Scarr E., Kitsoulis S., Hill C., et al. Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J Neurochem 72 (1999) 1593-1599
13. Erbagci A.B., Herken H., Koyluoglu O., Yilmaz N., and Tarakcioglu M. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm 10 (2001) 109-115
14. Garcia-Vallejo J.J., Van Het Hof B., Robben J., Van Wijk J.A., Van Die I., Joziasse D.H., et al. Approach for defining endogenous reference genes in gene expression experiments. Anal Biochem 329 (2004) 293-299
15. Ghavami A., Hunt R.A., Olsen M.A., Zhang J., Smith D.L., Kalgaonkar S., et al. Differential effects of regulator of G protein signaling (RGS) proteins on serotonin 5-HT1A, 5-HT2A, and dopamine D2 receptor-mediated signaling and adenylyl cyclase activity. Cell Signal 16 (2004) 711-721
16. Gladkevich A., Kauffman H.F., and Korf J. Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 559-576
17. Goff D.C., Midha K.K., Sarid-Segal O., Hubbard J.W., and Amico E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl) 117 (1995) 417-423
18. Gold S.J., Heifets B.D., Pudiak C.M., Potts B.W., and Nestler E.J. Regulation of regulators of G protein signaling mRNA expression in rat brain by acute and chronic electroconvulsive seizures. J Neurochem 82 (2002) 828-838
19. Grimaldi B., and Fillion G. 5-HT-moduline controls serotonergic activity: implication in neuroimmune reciprocal regulation mechanisms. Prog Neurobiol 60 (2000) 1-12
20. Huang X.F., Han M., Huang X., Zavitsanou K., and Deng C. Olanzapine differentially affects 5-HT(2Aand2C) receptor mRNA expression in the rat brain. Behav Brain Res 171 (2006) 355-362
21. Ilani T., Ben-Shachar D., Strous R.D., Mazor M., Sheinkman A., Kotler M., et al. A peripheral marker for schizophrenia: increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc Natl Acad Sci U S A 98 (2001) 625-628
22. Kaplan G.B., Leite-Morris K.A., and Keith D.J. Differential effects of treatment with typical and atypical antipsychotic drugs on adenylyl cyclase and G proteins. Neurosci Lett 273 (1999) 147-150
23. Kim E., Arnould T., Sellin L., Benzing T., Comella N., Kocher O., et al. Interaction between RGS7 and polycystin. Proc Natl Acad Sci U S A 96 (1999) 6371-6376
24. Kim Y.K., Kim L., and Lee M.S. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 44 (2000) 165-175
25. Kronfol Z., and Remick D.G. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 157 (2000) 683-694
26. Larminie C., Murdock P., Walhin J.P., Duckworth M., Blumer K.J., Scheideler M.A., et al. Selective expression of regulators of G-protein signaling (RGS) in the human central nervous system. Brain Res Mol Brain Res 122 (2004) 24-34
27. Liew C.C., Ma J., Tang H.C., Zheng R., and Dempsey A.A. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med 147 (2006) 126-132
28. Maes M., Bocchio Chiavetto L., Bignotti S., Battisa Tura G.J., Pioli R., Boin F., et al. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 54 (2002) 281-291
29. Malarstig A., Tenno T., Jossan S., Aberg M., and Siegbahn A. A quantitative real-time PCR method for tissue factor mRNA. Thromb Res 112 (2003) 175-183
30. Mirnics K., Middleton F.A., Lewis D.A., and Levitt P. Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends Neurosci 24 (2001) 479-486
31. Mirnics K., Middleton F.A., Stanwood G.D., Lewis D.A., and Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 6 (2001) 293-301
32. Monteleone P., Di Lieto A., Martiadis V., Bartoli L., and Maj M. Correlations between negative symptoms and peripheral G protein levels in mononuclear leukocytes of deficit and nondeficit schizophrenics. Preliminary results. Eur Arch Psychiatry Clin Neurosci 252 (2002) 214-218
33. Muller N., Riedel M., Ackenheil M., and Schwarz M.J. The role of immune function in schizophrenia: an overview. Eur Arch Psychiatry Clin Neurosci 249 Suppl 4 (1999) 62-68
34. Nadon R., and Shoemaker J. Statistical issues with microarrays: processing and analysis. Trends Genet 18 (2002) 265-271
35. Opeskin K., Dean B., Pavey G., Hill C., Keks N., and Copolov D. Neither protein kinase C nor adenylate cyclase are altered in the striatum from subjects with schizophrenia. Schizophr Res 22 (1996) 159-164
36. Pachot A., Blond J.L., Mougin B., and Miossec P. Peptidylpropyl isomerase B (PPIB): a suitable reference gene for mRNA quantification in peripheral whole blood. J Biotechnol 114 (2004) 121-124
37. Qu Y., Chang L., Klaff J., Seemann R., and Rapoport S.I. Imaging brain phospholipase A2-mediated signal transduction in response to acute fluoxetine administration in unanesthetized rats. Neuropsychopharmacology 28 (2003) 1219-1226
38. Romero G., Perez M.P., Carceller A., Monroy X., Farre A.J., and Guitart X. Changes in phosphoinositide signalling activity and levels of the alpha subunit of G(q/11) protein in rat brain induced by E-5842, a sigma(1) receptor ligand and potential atypical antipsychotic. Neurosci Lett 290 (2000) 189-192
39. Rothermundt M., Arolt V., and Bayer T.A. Review of immunological and immunopathological findings in schizophrenia. Brain Behav Immun 15 (2001) 319-339
40. Silver H. Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 7 (2001) 283-304
41. Silver H., and Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 31 (1992) 698-704
42. Silver H., Nassar A., Aharon N., and Kaplan A. The onset and time course of response of negative symptoms to add-on fluvoxamine treatment. Int Clin Psychopharmacol 18 (2003) 87-92
43. Simpson G.M., and Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212 (1970) 11-19
44. Spina E., De Domenico P., Ruello C., Longobardo N., Gitto C., Ancione M., et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 9 (1994) 281-285
45. Sullivan P.F., Fan C., and Perou C.M. Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 141 (2006) 261-268
46. Talkowski M.E., Chowdari K., Lewis D.A., and Nimgaonkar V.L. Can RGS4 polymorphisms be viewed as credible risk factors for schizophrenia? A critical review of the evidence. Schizophr Bull 32 (2006) 203-208
47. Tang Y., Gilbert D.L., Glauser T.A., Hershey A.D., and Sharp F.R. Blood gene expression profiling of neurologic diseases: a pilot microarray study. Arch Neurol 62 (2005) 210-215
48. Taoka H., Hamamura T., Endo S., Miki M., Lee Y., Miyata S., et al. G(olf) protein levels in rat striatum are increased by chronic antidepressant administration and decreased by olfactory bulbectomy. Life Sci 79 (2006) 462-468
49. Tardito D., Maina G., Tura G.B., Bogetto F., Pioli R., Ravizza L., et al. The cAMP-dependent protein kinase substrate Rap1 in platelets from patients with obsessive compulsive disorder or schizophrenia. Eur Neuropsychopharmacol 11 (2001) 221-225
50. Tian J., Chau C., Hales T.G., and Kaufman D.L. GABA(A) receptors mediate inhibition of T cell responses. J Neuroimmunol 96 (1999) 21-28
51. Toyooka K., Watanabe Y., Iritani S., Shimizu E., Iyo M., Nakamura R., et al. A decrease in interleukin-1 receptor antagonist expression in the prefrontal cortex of schizophrenic patients. Neurosci Res 46 (2003) 299-307
52. Ward R.P., and Dorsa D.M. Molecular and behavioral effects mediated by Gs-coupled adenosine A2a, but not serotonin 5-HT4 or 5-HT6 receptors following antipsychotic administration. Neuroscience 89 (1999) 927-938
53. Wilson C.J., Finch C.E., and Cohen H.J. Cytokines and cognition - the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc 50 (2002) 2041-2056
54. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Cao L.Y., and Shen Y.C. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 57 (2002) 247-258
55. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., and Shen Y.C. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry 65 (2004) 940-947